Analysis Of Income And Expense [Abstract]

BerGenBio - Filing #2615544

Concept	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue	—	—	—	774,000 NOK	—	601,000 NOK	—	—
Material income and expense [abstract]
Finance income (cost)	—	—	—	5,100,000 NOK	—	4,062,000 NOK	—	—
Operating expense	—	—	—	315,237,000 NOK	—	261,692,000 NOK	—	—
Expenses by nature [abstract]
Classes of employee benefits expense [abstract]
Short-term employee benefits expense [abstract]
Wages and salaries	—	—	—	69,929,000 NOK	—	48,832,000 NOK	—	—
Other employee expense	—	—	—	4,116,000 NOK	—	11,346,000 NOK	—	—
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]
Depreciation and amortisation expense [abstract]
Depreciation expense	—	—	—	1,312,000 NOK	—	726,000 NOK	—	—
Other expenses, by nature	—	—	—	239,880,000 NOK	—	200,788,000 NOK	—	—
Disclosure of attribution of expenses by nature to their function [text block]	—	—	—	—	—	—	—	—
Disclosure of attribution of expenses by nature to their function [abstract]
Disclosure of attribution of expenses by nature to their function [line items]
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	112,000 NOK	—	—	112,000 NOK	—	0 NOK	—	—
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	309,476,000 NOK	0 NOK	0 NOK	309,476,000 NOK	0 NOK	257,029,000 NOK	257,029,000 NOK	0 NOK